KR910019966A - 시마테롤의 거울상이성체의 분리, (-)-시마테롤 및 약학 조성물 또는 능률 증진제로서 이들의 용도 - Google Patents

시마테롤의 거울상이성체의 분리, (-)-시마테롤 및 약학 조성물 또는 능률 증진제로서 이들의 용도 Download PDF

Info

Publication number
KR910019966A
KR910019966A KR1019910007085A KR910007085A KR910019966A KR 910019966 A KR910019966 A KR 910019966A KR 1019910007085 A KR1019910007085 A KR 1019910007085A KR 910007085 A KR910007085 A KR 910007085A KR 910019966 A KR910019966 A KR 910019966A
Authority
KR
South Korea
Prior art keywords
tartaric acid
isopropylamino
cyano
phenyl
ethanol
Prior art date
Application number
KR1019910007085A
Other languages
English (en)
Other versions
KR0183024B1 (ko
Inventor
레제만 볼프강
뒤르 아돌프
엥겔하르츠 귄터
Original Assignee
에베르하르트 리히터, 칼 요트. 슐테
베링거 인겔하임 베트메디카 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에베르하르트 리히터, 칼 요트. 슐테, 베링거 인겔하임 베트메디카 게엠베하 filed Critical 에베르하르트 리히터, 칼 요트. 슐테
Publication of KR910019966A publication Critical patent/KR910019966A/ko
Application granted granted Critical
Publication of KR0183024B1 publication Critical patent/KR0183024B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Birds (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

시마테롤의 거울상이성체의 분리, (-)-시마테롤 및 약학 조성물 또는 능률 증진제로서 이들의 용도.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. (-)-1-(4′-아미노-3′-시아노-페닐)-2-이소프로필아미노-에탄올 및 이의 산부가염.
  2. 제1항에 있어서, 본질상 광학적으로 순수한 것임을 특징으로 하는 화합물.
  3. 제1항에 있어서, 적어도 ee=90%의 광학적 순도를 가짐을 특징으로 하는 화합물.
  4. 제1항에 있어서, 적어도 ee=94%의 광학적 순도를 가짐을 특징으로 하는 화합물.
  5. 제1내지 4항중 적어도 한 항에 따른 화합물의 생릭적으로 허용되는 산부가염.
  6. 임의로 하나이상의 불활성 담체 및/또는 희석제와 함께 제1내지 4항중 적어도 한 항에 따른 화합물 또는 제5항에 따른 생리적으로 허용되는 산부가염을 함유하는 약학 조성물.
  7. 비만증, 폐색성 폐 변화, 알레르기성 기관지 천식, 경련성 기관지염, 염증 또는 조산을 치료하는데 적합한 약학 조성물을 제조하는데 제 1내지 5항중 적어도 한 항에 따른 화합물을 사용하는 용도.
  8. 제 1내지 5항중 적어도 한 항에 따른 화합물을 비-회학적 방법에 의해 하나이상의 불활성 담체 및/또는 희석제에 혼입함을 특징으로 하는 제6항에 따른 약학 조성물을 제조하는 방법.
  9. 동물의 능률 증진제로서 제 1내지 5항중 적어도 한 항에 따른 화합물을 사용하는 용도
  10. 제 1내지 5항중 적어도 한 항에 따른 화합물을 함유하는, 동물사료제조용 도물 사료 및 전혼합물.
  11. 제 1내지 5항중 적어도 한 항에 따른 화합물을 함유하는 동물에 대한 능률 증진제.
  12. 제 1내지 5항중 적어도 한 항에 따른 화합물을 증량제, 희석제와 영양제 및 임의로 다른 애주번트와 혼합함을 특징으로 하여, 동물에 대한 능률 증진제를 제조하는 방법.
  13. 1-(4′-아미노-3′-시아노-페닐)-2-이소프로필아미노-에탄올과 적어도 2당량의 광학적으로 활성적인 이염기성 보조산, 예컨대 (-)-0,0′-디벤조일-L-타르타르산,(+)-0,0′-디벤조일-D-타르타르산,(-)-0,0′-디톨릴-L-타르타르산 또는 (+)-0,0′-디톨릴-D-타르타르산을 각각의 보조산에 특징적인 온도범위 아래로 온도가 내려가지 않도록 하면서 적합한 용매에 용해시켜 1-(4′-아미노-3′-시아노-페닐)-2-이소프로필아미노-에탄올을 결정시키고 결정된 부분 입체 이성체염을 분리시킨 후 거울상 이성체 염기를 유리시키고 필요에 따라 이렇게 수득된 거울상 이성체 염기를 이의 생리적으로 허용되는 산부가염으로 전환시킴을 특징으로 하여, (-)-1-(4′-아미노-3′-시아노-페닐)-2-이소프로필아미노-에탄올과 (+)-1(4′-아미노-3′-시아노-페닐)-2-이소프로필아미노-에탄올을 제조하는 방법.
  14. 제13항에 있어서, 보조산으로서 (+)-0,0′-디벤조일-L-타르타르산을 25℃이상의 온도에서 사용함을 특징으로 하는 방법.
  15. 1-(4′-아미노-3′-시아노-페닐)-2-이소프로필아미노-에탄올과 광학적으로 활성적인 이염기성 보조산, 예컨대 (-)-0,0′-디벤조일-L-타르타르산 또는 (+)-0,0′-디벤조일-D-타르타르산, (-)-0,0′-디톨릴-L-타르타르산 또는 (+)-0,0-디톨릴-D-타르타르산의 부분 입체 이성체 염.
  16. (-)-1-(4′-아미노-3′-시아노-페닐)-2-이소프로필아미노-에탄올-(+)-0,0′-디벤조일-D-타르타르산 수소염
  17. 1-(4′-아미노-3′-시아노-페닐)-2-이소프로필아미노-에탄올과 적어도 2당량의 광학적으로 활성적인 이염기성 보조산, 예컨대 (-)-0,0′-디벤조일-L-타르타르산 (+)-0,0′-디벤조일-D-타르타르산, (-)-0,0′-디톨릴-L-타르타르산 또는 (+)-0,0-디톨릴-D-타르타르산을 각각의 보조산에 특징적인 온도범위 이하로 온도가 내려가지 않도록 하면서 적합한 용매에 용해시켜 1-(4′-아미노-3′-시아노-페닐)-2-이소프로필아미노-에탄올을 결정시킨후, 결정된 부분입체 이성체염을 분리함을 특징으로 하여, 제15항 또는 제16항에 따른 부붑 입체 이성체염을 제조하는 방법.
  18. 제13항 또는 제17항에 있어서, 20℃이상, 바람직하게는 25내지 30℃에서 결정화 과정을 수행함을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910007085A 1990-05-04 1991-05-02 시마테롤의 거울상이성체의 분리, (-)-시마테롤 및 약학 조성물 또는 능률 증진제로서 이들의 용도 KR0183024B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4014252.3 1990-05-04
DE4014252A DE4014252A1 (de) 1990-05-04 1990-05-04 Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer

Publications (2)

Publication Number Publication Date
KR910019966A true KR910019966A (ko) 1991-12-19
KR0183024B1 KR0183024B1 (ko) 1999-05-15

Family

ID=6405664

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910007085A KR0183024B1 (ko) 1990-05-04 1991-05-02 시마테롤의 거울상이성체의 분리, (-)-시마테롤 및 약학 조성물 또는 능률 증진제로서 이들의 용도

Country Status (27)

Country Link
US (4) US5248695A (ko)
EP (2) EP0455155B1 (ko)
JP (1) JP2944777B2 (ko)
KR (1) KR0183024B1 (ko)
AR (1) AR247728A1 (ko)
AT (2) ATE124932T1 (ko)
AU (1) AU645313B2 (ko)
BG (1) BG60743B1 (ko)
CA (1) CA2041818C (ko)
CZ (1) CZ286389B6 (ko)
DE (3) DE4014252A1 (ko)
DK (2) DK0455155T3 (ko)
ES (2) ES2075255T3 (ko)
FI (1) FI109600B (ko)
GR (2) GR3017064T3 (ko)
HU (1) HU214335B (ko)
ID (1) ID966B (ko)
IE (2) IE69017B1 (ko)
IL (1) IL98030A (ko)
NO (1) NO174803B (ko)
NZ (1) NZ238032A (ko)
PT (1) PT97544B (ko)
RU (1) RU2002737C1 (ko)
SG (1) SG45439A1 (ko)
SK (1) SK279258B6 (ko)
TW (1) TW197415B (ko)
ZA (1) ZA913337B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4014252A1 (de) * 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer
GB2289842B (en) * 1991-04-05 1996-01-31 Sepracor Inc Improved use of ß2 bronchodilator drugs
GB9107196D0 (en) * 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
CA2247953A1 (en) * 1996-01-29 1997-07-31 E. Charles Pesterfield Jr. Method of treating undesired uterine contractions using optically pure r- or rr-isomers of adrenergic beta-2 agonists
EP1787529A3 (en) * 1997-04-30 2009-11-18 Courage Corporation Pty Ltd. Composition and methods using an eutomer
BR9815470A (pt) 1997-04-30 2001-10-23 Bridge Pharma Inc Composição e processo usando um eutÈmero
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
US7232837B2 (en) 1999-06-29 2007-06-19 Mcneil-Ppc, Inc. Stereoisomers with high affinity for adrenergic receptors
HUP0300832A2 (hu) * 2000-04-27 2003-08-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Új, lassú hatású bétamimetikumok, eljárás előállításukra és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US20030162459A1 (en) * 2002-02-27 2003-08-28 Osbon Robert Lindsay Method for producing a nonwoven fabric with enhanced characteristics
US20040235922A1 (en) * 2003-05-15 2004-11-25 Baile Clifton A. Compositions and methods for inducing adipose tissue cell death
SI1663197T1 (sl) * 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
SG124283A1 (en) * 2004-03-24 2006-08-30 Trusted Hub Ltd Document signature method & system
PL1719507T3 (pl) 2005-04-13 2010-12-31 Cipher Pharmaceuticals Inc Agoniści receptora beta2-adrenergicznego do leczenia chorób tkanki łącznej skóry
US20090181369A1 (en) * 2005-05-27 2009-07-16 George Q Daley Methods for the Treatment of Disease
US20090305225A1 (en) * 2005-06-13 2009-12-10 Galbraith Richard A Inhibition of Creatine Uptake to Promote Weight Loss
DK2925725T3 (en) 2012-12-03 2017-01-16 Pfizer androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL136601C (ko) * 1967-06-15
US4119710A (en) * 1972-12-18 1978-10-10 Boehringer Ingelheim Gmbh Bronchospasmolytic 1-(p-amino-phenyl)-2-amino-ethanols-(1) and salts
US4407819A (en) * 1980-08-25 1983-10-04 American Cyanamid Company Phenylethanolamine derivatives and acid addition salts thereof for the depression of fat deposition in warm blooded animals
US4814350A (en) * 1986-09-10 1989-03-21 American Cyanamid Company Method of treating diabetes with 5-[1-hydroxy-2-(isopropylamino)ethyl]anthranilonitrile
US4792546A (en) * 1986-12-05 1988-12-20 American Cyanamid Company Method for increasing weight gains and reducing deposition of fat in animals
DE4014252A1 (de) * 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer

Also Published As

Publication number Publication date
RU2002737C1 (ru) 1993-11-15
ES2109412T3 (es) 1998-01-16
BG94342A (en) 1994-06-30
CZ286389B6 (cs) 2000-03-15
CA2041818A1 (en) 1991-11-05
CS129291A3 (en) 1991-11-12
TW197415B (ko) 1993-01-01
EP0455155B1 (de) 1995-07-12
PT97544A (pt) 1992-01-31
US5395957A (en) 1995-03-07
HUT60999A (en) 1992-11-30
FI109600B (fi) 2002-09-13
EP0589488B1 (de) 1997-09-17
ZA913337B (en) 1993-01-27
DE59105957D1 (de) 1995-08-17
AR247728A1 (es) 1995-03-31
NO911746D0 (no) 1991-05-03
SK279258B6 (sk) 1998-08-05
NO911746L (no) 1991-11-05
DK0589488T3 (da) 1998-05-04
ATE124932T1 (de) 1995-07-15
AU645313B2 (en) 1994-01-13
NO174803C (ko) 1994-07-13
DE59108853D1 (de) 1997-10-23
DK0455155T3 (da) 1995-11-13
IL98030A (en) 1995-12-31
BG60743B1 (bg) 1996-02-29
AU7611191A (en) 1991-11-07
PT97544B (pt) 1998-08-31
ID966B (id) 1996-09-30
FI912151A (fi) 1991-11-05
FI912151A0 (fi) 1991-05-03
GR3017064T3 (en) 1995-11-30
GR3025547T3 (en) 1998-03-31
NO174803B (no) 1994-04-05
IL98030A0 (en) 1992-06-21
CA2041818C (en) 2003-02-11
JP2944777B2 (ja) 1999-09-06
US5648386A (en) 1997-07-15
IE69017B1 (en) 1996-07-24
HU911502D0 (en) 1991-11-28
EP0589488A1 (de) 1994-03-30
HU214335B (hu) 1998-03-02
JPH04225944A (ja) 1992-08-14
US5248695A (en) 1993-09-28
EP0455155A1 (de) 1991-11-06
ES2075255T3 (es) 1995-10-01
KR0183024B1 (ko) 1999-05-15
IE80651B1 (en) 1998-11-04
IE911507A1 (en) 1991-11-06
US5292753A (en) 1994-03-08
NZ238032A (en) 1996-02-27
ATE158277T1 (de) 1997-10-15
SG45439A1 (en) 1998-01-16
DE4014252A1 (de) 1991-11-07

Similar Documents

Publication Publication Date Title
KR910019966A (ko) 시마테롤의 거울상이성체의 분리, (-)-시마테롤 및 약학 조성물 또는 능률 증진제로서 이들의 용도
JP4795435B2 (ja) エソメプラゾール及びその塩の製造方法
JP2010159292A (ja) イミダゾリル化合物の塩酸塩一水和物
KR100280766B1 (ko) 페닐프로피온산의 실제적으로 순수한 에난티오머의 제조방법
JP2004536093A5 (ja) Ｒ−及びｓ−シタロプラムの混合物を分離することによってラセミシタロプラム及びｓ−もしくはｒ−シタロプラムを製造する方法
BG62066B2 (bg) (s)-(-)-1-пропил-2',6'-пипеколоксилидидов хидрохлорид монохидрат, метод за получаването му и фармацевтичен препарат, който го съдържа
HU188201B (en) Process for the resulation of trans-5-aryl-2,3,4,4a,5,9b-hexahydro-1h-pyrido/4,3-b/-indol derivatives
JP4015696B2 (ja) レボブピバカインと同類のピペリジンカルボキサニリド麻酔剤の製造に用いるラセミ化法
SK500302008A3 (sk) Spôsob výroby escitalopramu
JP4257573B2 (ja) Ｒ（＋）α−リポ酸の製造方法
BR102013004752A2 (pt) Processo para a transformação de medetomidina e recuperação do enantiômero indesejado
KR930004358B1 (ko) α-시아노-3-펜옥시-4-플루오로벤질 퍼메트레이트의 특정 에난티오머쌍의 제조방법
US4340751A (en) Method of optical resolution of (±)-2-amino-1-butanol and/or (±)-mandelic acid
JPH05502027A (ja) Ｒ（＋）　―テロジリン及びそれらの塩の製造方法
US6586634B1 (en) Process for the preparation on (1S,2R)-1-amino-2-indanol-(R,R)-tartrate methanol solvate
JPH10506384A (ja) 二環式ラクタム鏡像体の分離法
US8022232B2 (en) Method for manufacture of escitalopram
JPS5830301B2 (ja) Ｎ− ベンゾイル − トラシス −２− アミノシクロヘキサンカルボンサン ノ コウガクブンカツホウ
JPH01190661A (ja) ４，４′−ジヒドロキシジフエニルスルホンの精製法
JPH0259817B2 (ko)
JPH035382B2 (ko)
US4853477A (en) Separation of diastereomers of cyclopropanecarboxylic acid esters
JPS59134747A (ja) 光学的活性シクロプロパンカルボン酸の製法
JPS58124749A (ja) （±）−エリトロ−２−アミノ−１，２−ジフェニルエタノ−ルの光学分割法
KR20030032185A (ko) Ｎ,ｎ'-비스[2,3-디히드록시프로필]-2,4,6-트리요오드-5-아세틸아미도 이소 프탈아미드의 결정화방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]
G170 Re-publication after modification of scope of protection [patent]
FPAY Annual fee payment

Payment date: 20021126

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee